Novartis has a third FDA-approved indication ... For comparison, PNH and IgAN affect around 10-20 and 25 people per million, respectively. The approval follows positive results for Fabhalta ...

With future approvals of FABHALTA, the market size is expected to expand significantly in the coming years, driven by its potential to address unmet medical needs across multiple conditions ...

Apellis reported a net loss of $92.2 million for the first quarter of 2025 compared to a net loss of $66.4 million for the same period in 2024. Cash. As of March 31, 2025, Apellis had $358.4 million ...

The survey was conducted from March 10 through April 9, when the Department of Government Efficiency was in news ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... which also include paroxysmal nocturnal haemoglobinuria (PNH) and C3 glomerulopathy (C3G). The company acquired rights ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Medtronic today announced positive clinical outcomes from two studies of its pulsed field ablation (PFA) technologies.